(ASX:PTX) is presenting new preclinical data on OmniCAR at the Cell and Gene Meeting in the US. The company said the new results demonstrate the…

Clinical-stage oncology company Prescient Therapeutics (ASX: PTX) has revealed new data that demonstrates the capability of its OmniCAR cell therapy technology in killing multiple cancer cells.

Prescient’s OmniCAR platform could overcome the limitations of CAR-T treatments for cancer and it’s attracting the attention of leading global therapy decision makers.

Biotech company Prescient Therapeutics has given investors a glimpse into the progress of it’s next-generation CAR-T platform, OmniCAR , with data to be presented at…

In an announcement made this morning, the Melbourne-based company revealed its OmniCAR platform continues to demonstrate several key attributes in early studies. These attributes include…

Prescient Therapeutics Limited (ASX:PTX) is presenting new preclinical data on OmniCAR at the Cell & Gene Meeting on the Mesa in Carlsbad, California. Bringing together…

Prescient Therapeutics (PTX) will present new results for its OmniCAR drug at the Cell & Gene Meeting on Mesa in California. The conference brings together…

ASX-listed oncology player, Prescient Therapeutics Limited (ASX:PTX) is developing personalised medicines for difficult to treat cancers having unmet medical needs. The innovative product pipeline of…

Dr Rebecca Lim, Director of Scientific Affairs at Prescient Therapeutics (ASX: PTX), presented at the fifth annual Cell & Gene Therapy World Asia Conference 2021 last…

This year, the ASX healthcare index gained a little more than 10% year to date. The healthcare index acts as a benchmark for investors, reflecting…